Quick Summary
- A new collaboration between Novo Nordisk and Hims & Hers will enable obesity medication sales through the telehealth platform
- After-hours trading saw Hims shares spike 39% on the partnership announcement
- The agreement resolves ongoing litigation, including a patent violation case Novo filed recently
- Novo had previously ended a prior collaboration with Hims due to concerns about promotional methods and compounded medication distribution
- Regulatory authorities at the FDA had warned Hims about potential enforcement action regarding its $49 compounded semaglutide product
A surprising alliance has emerged between Novo Nordisk and Hims & Hers, with plans to distribute weight-loss medications via the telehealth company’s platform, bringing closure to a contentious legal battle that had intensified into patent litigation mere weeks earlier.
The arrangement was initially disclosed by Bloomberg News on Friday, according to sources with knowledge of the matter. Following the revelation, Hims shares experienced a dramatic 39% surge during after-hours trading.
Both organizations are preparing for an official announcement that could come as early as Monday. Details regarding the financial structure of the partnership remain undisclosed.
A Dramatic Reversal From Legal Conflict
The shift in relationship dynamics is remarkable. Only a month ago, Novo initiated patent infringement litigation against Hims following the telehealth firm’s brief introduction and subsequent withdrawal of a $49 compounded alternative to Novo’s weight-loss medication.
Regulatory officials at the U.S. Food and Drug Administration had additionally issued warnings about potential enforcement measures against Hims regarding its distribution of compounded semaglutide, the pharmaceutical compound found in Wegovy and Ozempic.
The combination of regulatory scrutiny and Novo’s legal action created significant challenges for Hims entering this week.
This marks the second attempt at cooperation between these entities. Novo terminated an initial partnership with Hims during the previous year, expressing dissatisfaction with Hims’ promotional approaches and its ongoing distribution of generic Wegovy alternatives.
The current agreement signals a renewed effort at working together, presumably under mutually acceptable conditions.
Implications for Each Company
For Novo, this collaboration provides an additional avenue to reach consumers with its branded weight-loss medications during a period of intensifying rivalry in the obesity pharmaceutical sector.
A representative from Novo stated the organization maintains “ongoing discussions with companies that can help improve patient access to FDA-approved medicines.” This represents the extent of Novo’s public commentary thus far.
Hims declined to provide a statement when contacted for this report.
For Hims, this partnership marks a significant strategic shift. The company had been emphasizing compounded semaglutide as an affordable substitute for Novo’s proprietary products.
This approach encountered obstacles when FDA officials declared semaglutide shortage conditions resolved earlier this year, essentially eliminating the regulatory justification for compounding facilities to continue manufacturing it.
Current Market Status
Hims equity climbed 39% during after-hours trading Friday. Throughout standard market hours, both NVO and HIMS experienced declines — NVO dropping 1.25% while HIMS fell 0.88%.
The official public announcement is anticipated to occur no later than Monday, March 9.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
